Top-line AML data disappoint for Astex and Otsuka

31 July 2018

Astex Pharmaceuticals has announced top-line results from a study of guadecitabine (SGI-110) showing the acute myeloid leukemia (AML) candidate failed to meet its co-primary endpoints.

The Cambridge, UK-based firm, which became a subsidiary of Otsuka (TYO: 4768) in 2013, has been studying the therapy in adults with previously untreated AML who are not eligible for chemo.

Top-line data show that complete response (CR) and overall survival (OS) parameters were not met. The firm says it will continue evaluation of the study’s secondary endpoints and safety data, and that these results will be presented in full at a later stage.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK